Treace Medical Concepts, Inc. revised revenue guidance for the year 2023. The company is updating its full-year 2023 revenue guidance to $182 million to $186 million, which represents approximately 28% to 31% growth over the Company?s 2022 revenue. This compares to the prior full-year 2023 revenue guidance of $191 million to $197 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.65 USD | +2.40% | -4.05% | -16.47% |
Mar. 25 | Treace Medical Concepts Treats 100,000 Patients With Lapiplasty Bunion Correction | MT |
Feb. 27 | Transcript : Treace Medical Concepts, Inc., Q4 2023 Earnings Call, Feb 27, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.47% | 660M | |
+72.92% | 12.36B | |
-19.68% | 7.83B | |
+16.20% | 7.21B | |
+6.78% | 5.97B | |
+7.49% | 5.14B | |
+23.97% | 4.43B | |
-18.95% | 3.9B | |
-41.54% | 2.2B | |
+1.24% | 2.02B |
- Stock Market
- Equities
- TMCI Stock
- News Treace Medical Concepts, Inc.
- Treace Medical Concepts, Inc. Revises Revenue Guidance for the Year 2023